6 News & Press Releases found
Altimmune Inc. News
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress on June 25, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research, will present the results of Altimmune’s recently completed ...
-
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in June 2022: Jefferies 2022 Global ...
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the results of the Company`s recently completed Phase 1 clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in ...
-
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5th Global NASH Congress on May 26-27, ...
-
Altimmune to Present at Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022: H.C. Wainwright Global ...
-
Altimmune Announces Initiation Of 48-Week Phase 2 MOMENTUM Trial Of Pemvidutide In Obesity
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide1 in subjects with ...